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Abstract
An 85-year-old Japanese man with a complaint of exertional dyspnea was admitted to our hospital. Sixty-three
years prior to admission at our hospital, he handled asbestos for 2 years in a factory. His chest computed tomography
showed a massive pericardial effusion leading to cardiac tamponade and right pleural plaque. After a pericardiocentesis
was performed, he recovered from cardiac failure caused by the cardiac tamponade. Pathological examination of the
pericardial effusion revealed malignant mesothelial cells. Therefore, he was diagnosed with primary pericardial
mesothelioma (PPM) related to asbestos exposure. Although his disease slowly progressed over 18 months, he
remained active without any adjuvant treatments such as chemotherapy. Long-term palliation in an aged patient
with PPM is rarely obtained using supportive care alone because the prognosis of PPM has been consistently
reported to be very poor and almost fatal within a year. Clinical oncologists and thoracic surgeons should be
aware of this disease because the accumulation of knowledge on PPM may lead to successful treatment even in
aged patients.
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Background
Primary pericardial mesothelioma (PPM) is an extremely
rare malignant neoplasm that arises from the pericardial
mesothelial cell layers [1]. The incidence of PPM has
been reported to be lower than 0.0022 % on an autopsy
series [2]. The prognosis of PPM, which is usually unre-
sectable, is very poor and almost consistently fatal [3].
Although no standard treatment has been established
for this disease entity, subxiphoid pericardiostomy
followed by drainage may be a safe procedure to provide
effective and durable symptomatic relief in critically ill
patients [3]. Here, we report an unusual clinical case,
wherein a pericardiocentesis led to long-term palliation
in a patient with PPM.
Case presentation
An 85-year-old man with 30 pack-year history of smok-
ing presented to our hospital with a complaint of chest
discomfort and exertional dyspnea persisting since a
month. He had suffered myocardial infarction 9 years
prior to this episode. He had worked as a gardener for
about 40 years. Prior to becoming a gardener, he han-
dled asbestos for 2 years in a factory. An electrocardio-
gram on admission revealed sinus tachycardia of 110
beats per minute. We observed a mild deterioration of
his oxygen saturation to 93 % on room air with effort.
His chest computed tomography (CT) revealed a massive
pericardial effusion and bilateral mild pleural effusions
without any tumors; these findings likely eliminated the
diagnoses of primary lung cancer and metastatic carcin-
omas (Fig. 1a). In addition, right pleural plaques were
clearly observed on chest CT after 8 months (Fig. 1b and
Additional file 1: Figure S1). Cardiac ultrasonography also
showed a massive pericardial effusion that caused a cardiac
tamponade. A needle pericardiocentesis was immediately
performed. The total amount of removed pericardial fluid
was 2300 mL. This fluid was a bloody exudate with a spe-
cific gravity of 1.032. The chest discomfort and dyspnea
markedly improved after the pericardiocentesis. To main-
tain the improvements in his symptoms, we initiated the
administration of loop diuretics (20 mg/day). No further
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drainage or invasive approaches were performed to con-
trol the pericardial effusion.
The carcinoembryonic antigen (CEA) level in the peri-
cardial effusion was 3.3 ng/mL. Pathological examination
of the cell-block specimen obtained from the pericardial
effusion revealed malignant mesothelial cells (Fig. 2a),
which were positively stained with calretinin, D2-40, and
Wilms’ tumor 1 (WT1) (Fig. 2b–d, respectively). Fur-
thermore, the cells were positively stained for p53 and
epithelial membrane antigen and negatively stained for
CEA (data not shown). Thus, he was diagnosed with
PPM. Considering his age, he did not receive any
chemotherapy. To date, only a loop diuretic has been
administered for controlling the pericardial effusion. He
was discharged on the 20th day of hospitalization. Chest
CT 8 (Fig. 1c) and 16 months (Fig. 1d) later revealed
that the pericardial effusion was well controlled. Although
his symptoms of general fatigue and trunk pain slowly but
steadily progressed and the pericardial effusion slightly
increased, he remained fully active 18 months after his
initial presentation.
Discussion
The treatments for PPM are surgical therapy, radiother-
apy, and chemotherapy. Most of the surgical therapy
comprises pericardial resection even when the tumor is
localized. It is mostly useful for preventing cardiac tam-
ponade or for tumor reduction [4]. Systemic chemother-
apy with the combination of platinum and pemetrexed
or the combination of doxorubicin, vincristine, and
cyclophosphamide has been found to be effective for
PPM in some reports [5–7]. The condition is usually
fatal within a year regardless of its treatment being suc-
cessful [3]. To the best of our knowledge, PPM is a rare
disease entity and no reliable clinical trials for systemic
chemotherapy have been conducted. The effectiveness of
systemic chemotherapy had been demonstrated mainly
through case reports. Because no large-scale clinical ran-
domized trial of chemotherapy or radiotherapy for PPM
has been performed yet, the evidence level for these
treatments is rather low. Therefore, although neither ra-
diation therapy nor chemotherapy has proven to be
beneficial, both have been used as adjuvant treatments
in patients with incomplete tumor resection or meta-
static disease. In the present case, because of the
patient’s age and the risk of adverse events caused by
chemotherapy, we performed best supportive care alone.
The patient remained fully active 18 months after his
initial presentation.
The cell-block specimen obtained from his pericardial
effusion was positively stained for calretinin, D2-40,
and WT1 and negatively stained for CEA. Because
Fig. 1 Findings from chest computed tomography. A chest computed tomography (CT) revealed massive pericardial effusion and bilateral pleural
effusions on admission (a). A chest CT after 8 months clearly showed pleural plaques (b yellow arrow heads). A chest CT revealed that the pleural
effusion was well-controlled for 8 months (c) and 16 months (d) after the initial treatment. The maximum thicknesses of the cavity in which the
pericardial effusion accumulated in Fig. 1a, c, and d were 34.8, 3.3, and 12.6 mm, respectively
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mesothelioma cells do not have a specific marker for
diagnosis, it is very difficult to make an adequate cyto-
logical diagnosis among the types of pulmonary adenocar-
cinoma cells. In general, useful diagnostic mesothelial
markers include calretinin, WT1, cytokeratin 5/6, and D2-
40. It has been recommended that at least two mesothelial
markers and two carcinoma markers with greater than
80 % sensitivity and specificity be used for the diagnosis of
mesothelioma when all clinical, radiologic, and histologic
features are concordant [8].
These findings indicated that the pericardial tumor
cells of this patient resembled epithelial mesothelioma
(EM). EM generally has a good prognosis compared to
sarcomatoid and biphasic mesothelioma. In particular,
well-differentiated papillary mesothelioma, a rare variant
of EM, is associated with a good prognosis owing to its
clinically indolent behavior and long survival period [9].
Although definite reasons for the long survival time
were not clear, we speculated that this favorable out-
come could be obtained because of the properties of the
tumor in this case.
The cause of PPM remains unknown, unlike that of
pleural mesothelioma. Although the pathogenesis of
PPM may not be related to asbestos exposure, Warren
et al. reported that PPM was likely to develop during
childhood and among patients with low levels of expos-
ure to asbestos [3]. Mensi et al. reported a high inci-
dence of occupational asbestos exposure among seven
patients with PPM (5/7 patients: 71.4 %, 95 % CI 29.0–
96.3) [10]. The asbestos exposure may be one of the
main causes of PPM. Although PPM generally occurs in
young people (median age, 46 years; range, 19–76) com-
pared to pleural or peritoneal mesothelioma [11, 12],
our case was an aged patient. Although his occupational
asbestos exposure had lasted for only 2 years when he
was young, pleural plaques detected on chest CT sug-
gested that his disease was related to asbestos exposure.
Conclusions
In conclusion, this aged patient with PPM experienced
an indolent clinical course with a long-term palliation
after pericardiocentesis and loop diuretics. Because PPM
is very rare, reporting the concise course of the disease
will contribute to the accumulation of clinical knowledge.
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Additional file 1: Figure S1. Detailed clinical course of the pleural
plaques detected in this case. Four chest computed tomographies (CTs)
at different time points revealed pleural plaques. A year before disease
onset (A), at the time of disease onset (B), 8 months after disease onset
(C), and 16 months after disease onset (D). (TIFF 708 kb)
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Fig. 2 Pathological findings from the cell-block specimen of pericardial effusion. Atypical large mesothelial cells had proliferated forming a tumor
nest. Hematoxylin–Eosin (a), calretinin (b), D2-40 (c), and Wilms’ tumor 1 (WT1) (d) (×1000)
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